omalizumab


Also found in: Medical, Acronyms, Wikipedia.

o·ma·liz·u·mab

 (ō′mə-lĭz′yə-măb′)
n.
A humanized monoclonal antibody, used as an intravenous drug to treat severe asthma.

[oma-, origin unknown + -li- (shortening and alteration of immunoglobulin, the molecule targeted by the drug) + -zu- (shortening of humanized) + m(onoclonal) a(nti)b(ody).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
In the study, which was not powered for efficacy endpoints, 51% of those who received 72 mg subcutaneously every 4 weeks had a Hives Severity Score of 0 by week 12, compared with 42% of those who received 240 mg every 4 weeks and 26% of those taking the omalizumab comparator.
Omalizumab is a chimeric humanized monoclonal antibody composed of 95% human and 5% murine sequence.
Bu yazida, tedaviye yanitsiz kronik kendiliginden gelisen urtiker, kronik otoimmun urtiker ve nedeni bilinmeyen anjiyoodem tanilari ile bolumumuzde izlenen ve H1-antihistaminik tedavilerine yanit vermeyen uc olguda omalizumab ile ilk dozdan baslayarak elde edilen tedavi basarisi sunulmustur.
Omalizumab, an anti-IgE monoclonal antibody, is recommended for patients at least 6 years of age with allergic asthma, as determined by in vitro reactivity to a perennial aeroallergen or positive skin test responses, and symptoms uncontrolled on GINA step 4 treatment.
The now completed Phase 1 study enrolled 168 healthy adult volunteers, randomized 1:1 to receive either a single 150 mg dose of GBR 310 subcutaneously (SC) or a single 150 mg dose of U.S.-sourced omalizumab SC.
Recently, the use of an anti-IgE monoclonal antibody, omalizumab, was introduced for the control of EOM [6, 7].
Nikolaos Syrigos, M.D., from Sotiria General Hospital in Athens, Greece, and colleagues retrospectively evaluated medical records from 20 patients (mean age 54.5 years; 75 percent women) with refractory CSU in order to assess correlations between demographic, clinical, and laboratory characteristics and omalizumab treatment outcomes.
The patients were treated with 300 mg omalizumab administered subcutaneously every 4 weeks for 6 months, following the conventional CSU protocol.
Therefore, it could be informative and clinically important to identify the biomarkers able to classify patients according to their phenotype, possibly identifying underlying immunological mechanisms (and therefore setting the disease "endotype"), to stratify patients according to their severity and prognosis, and to identify best responders to any given therapy, particularly to biologics such as omalizumab (Figure 1).
We present a case series focusing on the role of subcutaneous omalizumab in the treatment of CIU along with its safety profile in terms of immediate and late side effects.